The impact of comorbid type 2 diabetes on survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis focusing on lung cancer - Top-Institutions - MDSpire

The impact of comorbid type 2 diabetes on survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis focusing on lung cancer

  • By

  • Linlin Fan

  • Weijie Xu

  • Qiang Zhang

  • Jin Li

  • Wenhui Bai

  • May 11, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology

  • #2

    Johns Hopkins Sidney Kimmel Cancer Center
    Johns Hopkins Sidney Kimmel Cancer Center

    Baltimore, MD

    Key Differentiators

    • Oncology

  • #3

    Harvard Medical School
    Harvard Medical School

    Boston, MA

    Key Differentiators

    • Oncology

  • #4

    Northwestern University
    Northwestern University

    Chicago, IL

    Key Differentiators

    • Oncology

  • #5

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

Original Source(s)

The impact of comorbid type 2 diabetes on survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis focusing on lung cancer

  • by Linlin Fan, Weijie Xu, Qiang Zhang, Jin Li, Wenhui Bai

  • May 11, 2026

Related Content

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer